by Stephen Levin
On April 6, 1998, 83-year-old Fayard Nicholas, half of the famed Nicholas Brothers tap dancing duo, joined his brother Harold...
Re-Starting Heartport
Heartport was the darling of investors when it burst on the scene in 1996 with a new minimally-invasive cardiac surgery technology. The company's stratospheric IPO valuation quickly deflated as cardiac surgeons, proving more cautious than investors, have been slow in adopting Heartport's technique. Armed with new management and a new strategy, Heartport is regrouping, still convinced, in the face of major competitors using a different approach, that its technology represents the future of minimally-invasive cardiac surgery.
More from Innovation
• By
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
• By
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
More from In Vivo
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.